statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024 PR Newswire DUBLIN, April 17...

Jazz Pharmaceuticals to Report 2024 First Quarter Financial Results on May 1, 2024

Latest Ratings for JAZZ
 DateFirmActionFromTo Mar 2022HC Wainwright & Co.MaintainsBuy Mar 2022Piper SandlerMaintainsOverweight Mar 2022RBC CapitalMaintainsOutperform
 View More Analyst Ratings...

Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy...

Jazz Pharmaceuticals to Showcase Expansive Neuroscience Portfolio at American Academy of Neurology Annual Meeting

Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen research firms that are presently covering the stock...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Receives $195.08 Average Price Target from Brokerages

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Jazz Pharmaceuticals Completes Zanidatamab Biologics...

Jazz Pharmaceuticals Completes Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer

A month has gone by since the last earnings report for Jazz Pharmaceuticals (JAZZ). Shares have added about 1.3% in that time frame, underperforming the S&P 500.Will the recent positive trend...

Why Is Jazz (JAZZ) Up 1.3% Since Last Earnings Report?

Thompson Investment Management Inc. lifted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ  Free Report) by 24.9% in the 4th quarter, Holdings Channel.com reports. The fund owned 6,520...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by Thompson Investment Management Inc.

American Century Companies Inc. increased its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ  Free Report) by 18.1% during the 3rd quarter, according to the company in its most...

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Bought by American Century Companies Inc.

Jazz Pharmaceuticals (NASDAQ:JAZZ  Get Free Report)s stock had its overweight rating reissued by research analysts at Cantor Fitzgerald in a research report issued on...

Cantor Fitzgerald Reiterates Overweight Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Needham & Company LLC reissued their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ  Free Report) in a research note released on Wednesday, Benzinga reports. Needham & Company LLC...

Jazz Pharmaceuticals (NASDAQ:JAZZ) Earns Buy Rating from Needham & Company LLC

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Volume	424,856.00
52-Wk High	$146.70
52-Wk Low	$106.61

JAZZ Jazz Pharmaceuticals plc

About

Feed

News

Sentiment

Earnings

Fundamentals